Abstract
The oncogene microRNA-21 (miRNA; miR-21) is overexpressed in most solid organ tumours; however, a recent examination of stage II colorectal cancer (CRC) specimens suggests this may be a stromal phenomenon and not only a feature of cancer cells. In vitro and in vivo studies show that miR-21 has potent pro-metastatic effects in various malignant carcinoma cell lines. The tumour microenvironment has also been identified as a key actor during the metastatic cascade; however to date the significance of deregulated miR-21 expression within the cancer-associated stroma has not been examined. In the present study, a quantitative RT-PCR-based analysis of laser microdissected tissue confirmed that miR-21 expression is associated with a four-fold mean increase in CRC stroma compared with normal tissue. In situ hybridisation using locked nucleic acid probes localised miR-21 expression predominantly to fibroblasts within tumour-associated stroma. To study the molecular and biological impact of deregulated stromal miR-21 in CRC, stable ectopic expression was induced in immortalised fibroblasts. This resulted in upregulated α-smooth muscle actin expression implying miR-21 overexpression is driving the fibroblast-to-myofibroblast transdifferentiation. Conditioned medium from miR-21-overexpressing fibroblasts protected CRC cells from oxaliplatin-induced apoptosis and increased their proliferative capacity. 3D organotypic co-cultures containing fibroblasts and CRC cells revealed that ectopic stromal miR-21 expression was associated with increased epithelial invasiveness. Reversion-inducing cysteine-rich protein with kazal motifs, an inhibitor of matrix-remodelling enzyme MMP2, was significantly downregulated by ectopic miR-21 in established and primary colorectal fibroblasts with a reciprocal rise in MMP2 activity. Inhibition of MMP2 abrogated the invasion-promoting effects of ectopic miR-21. This data, which characterises a novel pro-metastatic mechanism mediated by miR-21 in the CRC stroma, highlights the importance of miRNA deregulation within the tumour microenvironment and identifies a potential application for stromal miRNAs as biomarkers in cancer.
Similar content being viewed by others
Main
Colorectal cancer (CRC) is a key public health issue, and accounts for the second highest cause of cancer-related death in Western societies.1 Metastases are the principle cause of death, and occur in 30% of patients at presentation and subsequently in >50% of patients after surgery with curative intent.2 The metastatic cascade is a complex, multistep process3 and despite the introduction of chemotherapy and newer targeted therapies, the majority of patients with metastases remain incurable.4, 5 An important feature of metastatic progression is the role had by the tumour microenvironment and the promotion of tumour growth, invasion and angiogenesis by the cancer-associated stroma.6, 7 The key cellular components of cancer-associated stroma are myofibroblasts, α-smooth muscle actin (SMA)-expressing cells that transdifferentiate from fibroblast progenitors in response to paracrine signals from the malignant epithelium.6 These cells also modulate the chemistry of the tumour microenvironment by producing matrix metalloproteinase enzymes (MMPs), MMP inhibitors, extracellular matrix (ECM) components, growth factors and cytokines.8 The dynamic and reciprocal interaction between stromal and malignant epithelial cells has a profound impact on tumour progression in vivo,9 and as stromal cells are less likely to acquire de novo mutations, evade anti-cancer immunity or develop drug resistance, the development of targeted therapies based on improved molecular characterisation of CRC stroma is an attractive prospect.10, 11
MicroRNAs (miRNAs) are a class of small highly conserved non-coding RNAs that provide widespread expressional control through repression of mRNA translation. They are strongly implicated in the pathogenesis of numerous malignancies,12 and hold promise as therapeutic targets as they regulate fundamental intracellular processes and are deregulated, often in a tissue- and tumour-specific manner, in all cancer types examined to date.13
In CRC, miRNAs derail a number of cellular signal transduction and cell survival pathways including the Wnt/β-catenin pathway, epidermal growth factor receptor pathway and p53 function connecting miRNA biology to known mutational events in the classical adenoma–carcinoma sequence of malignant transformation and potentially to each of the hallmarks of cancer.14
High throughput profiling studies have also uncovered miRNA-mediated pathways in the regulation of metastasis. One miRNA with particular prominence is miRNA-21 (miR-21), which in diverse cancer cell lines regulates apoptosis and metastasis by suppressing genes such as phosphate and tensin homologue (PTEN),15 programmed cell death 4 (PDCD4)16 and MMP inhibitors, reversion-inducing cysteine-rich protein with Kazal motifs, (RECK) and tissue inhibitor of metalloproteinase 3.17
Interestingly, Nielsen et al.18 recently demonstrated that miR-21 overexpression in stage II CRC occurs in the stroma rather than in the epithelium. In a separate study, miR-21 suppression with antisense inhibitors was shown to prevent the fibroblast-to-myofibroblast transdifferentiation in response to transforming growth factor beta (TGF-β).19 Together, these data suggest that the pro-metastatic influence of miR-21 may be mediated through the tumour microenvironment; however, biological and functional evidence to support this model has not been deeply investigated.
The aims of the current study are to provide multimodal validation of miR-21 expression patterns in CRC and to gain improved understanding of the pathological relevance of deregulated stromal miR-21 by dissecting out molecular interactions within the tumour microenvironment.
Results
MiR-21 expression localises to fibroblast-like cells in the CRC stroma
Mir-21 has been shown to be upregulated in different cancers including CRC.20, 21, 22, 23, 24 As most of these studies utilised pieces of tumour tissue containing tumour and non-tumour cells for the detection of miR-21 expression, the relative contribution of stromal/cancers cells to the observed miR-21 upregulation is not clearly established. To identify the source of overexpressed miR-21 in CRC, we used an in situ hybridisation (ISH) technique. Highly sensitive locked nucleic acid (LNA) probes showed specific and predominant staining in fibroblast-like cells in the stroma of all CRC specimens examined. Crucially, tumour epithelium and benign tissue showed only weak and sporadic expression of miR-21 in mononuclear cells (Figure 1a). To quantify the overexpression of miR-21, we performed laser microdissection (LMD; Figure 1b) followed by quantitative PCR (qPCR) using TaqMan probes (Applied Biosystems, Foster City, CA, USA). We found that mean miR-21 expression was fourfold higher in the LMD stroma of CRC specimens compared with paired normal tissue (P=0.005, Figure 1c). To prove the efficiency of LMD, we also conducted qPCR assays to quantify expression of epithelial and mesenchymal markers in microdissected tissue. Microdissected stroma expressed high levels of mesenchymal cell-specific vimentin (VIM) mRNA and fibroblast-specific protein 1 (FSP1; S100 calcium-binding protein A4, S100A4; P<0.05) and low levels of epithelium-specific E-Cadherin (CDH1; P=0.05; Figure 1d).
The impact of stable ectopic miR-21 overexpression in immortalised stromal fibroblasts
To assess the biological significance of upregulated stromal miR-21, its ectopic expression was stably induced in an established human fibroblast cell line (MRC5). MiR-21-overexpressing MRC5 cells (MRC521) underwent striking morphological change, adopting enlarged and elongated forms, which was accompanied by minor increases in α-SMA expression compared with identical passage scrambled control-transfected (MRC5SCC) cells (Figure 2a). Fibroblasts showing similar morphological features are considered as myofibroblasts and characterised by increased α-SMA containing intracellular filaments. Secreted molecules from cancer cells such as TGF-β are responsible for fibroblast-to-myofibroblast transdifferentiation.8 Myofibroblasts are often observed in the tumour microenvironment and their presence has been proposed as an independent marker of poor prognosis.25
To assess whether miR-21 overexpression primes myofibroblast transdifferentiation or provokes an intermediate differentiation state, MRC521 and MRCSCC cells were treated with conditioned media (CM) extracted from SW480 CRC cells (CMSW480) or TGF-β at 2 ng/ml or 10 ng/ml final concentration, respectively. After 3 days, α-SMA expression was assessed by immunofluorescence revealing that stress fibre formation had occurred in a significantly greater proportion of MRC521 cells than that of MRC5SCC cells in response to CMSW480 and low dose TGF-β. As anticipated, treatment with higher TGF-β doses induced large numbers of both MRC5SCC and MRC521 cells to undergo myofibroblast transdifferentiation. Stress fibre deposition was not found in significant numbers of MRC521 or MRC5SCC cells in the untreated group (Figure 2b).
These results suggest that although miR-21 expression alone is insufficient to drive myofibroblast transdifferentiation, it may condition/facilitate fibroblasts to acquire the myofibroblast state.
Medium supernatant from miR-21-overexpressing fibroblasts increases the proliferative capacity of CRC cells and protects them from oxaliplatin-induced apoptosis
The reciprocal interaction between cancer cells and tumour stroma is a contributing factor in carcinoma progression. To assess the effect of stromal miR-21 manipulation on the cell fate of CRC cells, we investigated their proliferative properties and resistance to apoptosis. After a 24- or 48-h incubation with CM from MRC521 cells (CM21), the mean cell density of SW480 cells increased by 40% (P<0.03) and 93% (P=0.01) compared with controls (CM from MRC5SCC; CMSCC), respectively. Under the same conditions, another CRC cell line (DLD1) showed an 18% (t=24 h, P=0.09) and 66% (t=48 h, P=0.01) mean cell density increase compared with controls (Figure 3a).
We also evaluated the comparative effect of CM21 or CMSCC treatment on oxaliplatin-mediated apoptosis. We found that oxaliplatin, a first-line cytotoxic agent for the treatment of patients with stage III and IV CRC, was less effective at inducing apoptosis and cell death in CM21-treated CRC cells compared with CMSCC-treated controls (Figures 3b and c).
Medium supernatant from miR-21-overexpressing fibroblasts enhances CRC cell invasion
Increased motility and invasion are critical physiological processes in the course of metastasis. To assess whether stromal miR-21 alters the invasive properties of CRC cells, we used CM from miR-21 and miR-SCC stably transfected cells (CM21/CMSCC) as chemoattractant and performed transwell invasion assays. CM21 was associated with 1.7- (P<0.02) and 1.8-fold (P=0.03) increases in invasiveness of SW480 and DLD1 CRC epithelial cells, respectively, compared with CMSCC controls (Figure 4a). In order to examine invasiveness further, we used organotypic culture conditions that closely resemble the in vivo tumour microenvironment. To achieve this, we embedded MRC521 or MRC5SCC cells into gels containing ECM components (matrigel and collagen) and seeded CRC cells as a layer on the top. Our results showed a 2.5-fold (P<0.005) increase in the invasion of SW480 cells into the stroma containing MRC521 cells compared with control (Figure 4b). Green fluorescent protein (GFP)-positive cells within the stroma confirmed the presence of fibroblasts stably transfected with IRES-driven miRNA/GFP co-expression plasmid (Figure 4c). These results suggest that stromal expression of miR-21 can induce enhanced motility and invasion of CRC cells.
MiR-21 targets RECK in the CRC stroma
To streamline the search for mechanistic explanations for the novel observation that miR-21 overexpression in fibroblasts enhances CRC invasiveness, we turned our focus to a regulator of ECM remodelling known to be targeted by miR-21:17 RECK is a negative regulator of MMP activity. RECK mRNA has been shown to be targeted directly by miR-21 in mutated/unmutated 3′-untranslated region luciferase reporter assays in several cell lines and in numerous tumour contexts.17, 26 We found that stable miR-21-expressing fibroblasts express reduced RECK mRNA and protein (Figures 5a and b). These results provide mechanistic explanation why stromal expression of miR-21 is a contributing factor to invasiveness of CRC tumours. In order to validate the functional consequences of miR-21 expression in relation to MMP activation, we stained sections of organotypic cultures with RECK. We observed fibroblast-specific expression of this protein in MRC5SCC but not MRC521 specimens consistent with our previous findings that MRC521-containing stroma significantly enhanced invasion of SW480 CRC cells (Figure 5c).
Finally, to observe the relationship between miR-21 and its target RECK in a more physiological setting, primary colon fibroblasts (PCFs) were obtained and transiently transfected with miR-21/GFP or miR-SCC/GFP co-expression plasmid. After 48 h, transfection cells were fixed for the purpose of immunofluorescence labelling. Cells transfected with scrambled control plasmid demonstrated baseline RECK expression. In contrast, miR-21-transfected cells displayed decreased RECK expression in proportion with transfection efficiency as cells exhibiting the most intense GFP signal were also associated with the most diminished RECK fluorescence signal (Figure 5d).
MiR-21-dependent RECK downregulation is associated with a reciprocal rise in MMP2 activity – CRC invasion is MMP2 dependent
The key action of RECK is to inhibit the otherwise unchecked activity of MMPs involved in the breakdown of ECM. To assess whether RECK downregulation in response to ectopic miR-21 expression leads to increased MMP activity, CM21 and CMSCC were analysed by gelatin zymography. In this assay, a dominant band corresponding to MMP2 was consistently detected and miR-21 upregulation led to a significantly increased gelatinase activity compared with controls (Figures 6a and b).
Importantly, the increased invasive effect associated with CM21 compared with CMSCC in transwell assays was partially abrogated in the presence of 25 μM MMP2 inhibitor (Figure 6c), suggesting stromal miR-21-dependent SW480 CRC cell invasion is mediated in part by increased MMP2 activity.
Discussion
Targeted therapeutic strategies based on an improved understanding of the molecular biology of malignancy have been applied to CRC with little success;4, 5 however, recent insights linking deregulated miRNA expression to malignant change16, 27 and to the acquisition of metastatic capabilities17, 28, 29, 30, 31 have brought renewed optimism. Although cancer-associated stroma is an attractive target for novel drug development, researchers have focused mainly on deregulated miRNAs in cancer epithelial cells, and as a consequence the identity and the role of stromal miRNAs remains poorly understood.
Nevertheless, recent studies have provided valuable insights: Bronisz et al.32 powerfully demonstrated that downregulation of miR-320 in mammary stromal fibroblasts reprograms the tumour microenvironment by activating a pro-oncogenic secretome; and Yao et al.19 demonstrated that myofibroblast transdifferentiation from progenitor fibroblasts in response to TGF-β could be prevented using specific antisense inhibitors of miR-21. The implications of these data, which suggest a regulatory role for miRNAs in fibroblast differentiation and phenotype, are potentially profound as cancer-associated fibroblasts, including myofibroblasts, are powerful regulators of invasive cancer growth, angiogenesis and disease progression (reviewed by De Wever et al.8).
Studies of various solid organ tumours have linked elevated miR-21 expression to advancing tumour stage, venous invasion, lymph node and distant metastases, poor disease-free survival and poor overall survival.33, 34 In CRC cell lines, miR-21 correlates inversely with target protein PDCD4 expression, and anti-miR-21 reduces invasiveness and capacity to form metastases in chicken-embryo-metastasis assays.16 MiR-21 upregulation enhances proliferation in pancreatic, glioblastoma and CRC cell lines,20, 21, 22 and as a known anti-apoptotic factor23 it promotes resistance to radiotherapy and chemotherapy in several tumour contexts.24
Crucially however, the chemoresistance and pro-metastatic functions attributed to miR-21 are all mediated by the malignant epithelium.
In the present study, we used high sensitivity TaqMan qPCR assays to demonstrate that upregulated miR-21 expression occurs not in CRC cells but in the cancer-associated stroma. Furthermore, ISH pinpointed miR-21 overexpression exclusively to fibroblast-like cells. Prompted by these results, analysis of upregulated miR-21 expression in the stroma became an important priority. The most striking effect of stable miR-21 expression in MRC5 fibroblasts was the adoption of an elongated and enlarged morphology, accompanied by a minor increase in α-SMA expression. Although suggestive of myofibroblast differentiation status, in the absence of significant stress fibre deposition, it was essential to conclude that miR-21 overexpression alone is insufficient to drive fibroblast-to-myofibroblast transdifferentiation.
Nevertheless, fibroblasts in which miR-21 had been ectopically expressed did share a number of tumour-promoting characteristics with myofibroblasts. Treatment with CM21 was associated with increased proliferation and reduced oxaliplatin-induced apoptosis in CRC cell lines. CM21 was also associated with increased CRC cell invasiveness in in vitro transwell invasion assays and organotypic models.
To characterise the mechanism underlying this novel pro-invasive effect, we turned our attention to regulators of ECM remodelling known to be targeted by miR-21. RECK has been shown to be targeted by miR-21 in glioma models, and as a negative regulator of MMP activity it inhibits tumour invasion.17 RECK is downregulated in the majority of CRC specimens compared with normal tissue, and low expression is associated with poor outcome.35 It is a membrane anchored glycoprotein and its main function is to inhibit MMP2, MMP9 and MT1-MMP activity.36
In this study, we demonstrated that miR-21 negatively regulates RECK protein expression in cultured and PCFs transfected with a miR-21/GFP co-expression plasmid.
RECK is known to regulate MMP2 via a number of post-transcriptional mechanisms and has a role in other cancer relevant biological pathways.37 We demonstrated that ectopic miR-21 expression in MRC5 fibroblasts increases MMP2 activity and by using specific inhibitors to show invasion by SW480 CRC cells is MMP2 dependent, we highlighted a possible mechanism through which upregulated stromal miR-21 expression increases invasion in vitro. In cardiac fibroblasts, miR-21-induced MMP2 upregulation is associated with a PTEN-dependent mechanism,38 and although PTEN is also a miR-21 target, we have focussed on an alternative mechanism because in vivo MMP2 and RECK expression are inversely correlated and have prognostic relevance in CRC.39
A description of our major findings is provided in Figure 7. In summary, we confirm that deregulation of the key oncomiR, miR-21, is a stromal phenomenon in CRC. Our data also shows that ectopic miR-21 expression in cultured fibroblasts modulates the cytotoxic impact of oxaliplatin, promotes CRC proliferation and enhances epithelial invasion. Changes in cell morphology and increased α-SMA expression were observed in the immortalised MRC521 fibroblasts but not control cells (MRC5SCC). MRC521 fibroblasts also underwent myofibroblast transdifferentiation more readily in response to TGF-β than control cells, suggesting that the functional impact of stromal miR-21 on the hallmark processes of tumour progression may be linked to the myofibroblast phenotype. Furthermore, ectopic miR-21 expression in fibroblasts resulted in downregulated RECK expression and increased MMP2 activity.
This study highlights the importance of the stroma in CRC progression and presents an interesting perspective for the development of novel, stroma-targeted drugs.
Materials and Methods
Patients and samples
Samples from patients with biopsy-proven CRC (tumour tissue and uninvolved proximal mucosa) were obtained fresh at the time of surgery and snap frozen in liquid nitrogen before being deposited in a designated UK Human Tissue Act-approved tumour bank. All patients provided informed consent in accordance with the Helsinki protocol and the study was approved by the regional research ethics committee. Pathological verification of diagnosis and staging was in accordance with the Association of Coloproctology of Great Britain and Ireland guidelines on the management of CRC.
Ten adenocarcinomas, with a priori decided tumour stage (five Dukes A and five Dukes C) and their paired uninvolved proximal mucosa were selected at random before LMD and RNA extraction.
LMD and RNA extraction
Frozen human tissue specimens were sectioned to 10-μm-thickness onto membrane-mounted slides (Molecular Devices, Sunnyvale, CA, USA). Sections were fixed in 75% ethanol, stained with 1% Cresyl Violet (Sigma, Dorset, UK) and dehydrated with increasing concentrations of ethanol before being air dried. LMD was performed using the Leica AS microdissection platform (Leica Microsystems, Milton Keynes, UK; Figure 1b) and cut stroma was collected directly into 50 μl cell lysis buffer (RNAqueous Micro Kit, Applied Biosystems). Total RNA was extracted using the RNAqueous Micro Kit (Applied Biosystems).
TaqMan qPCR quantitation
Singleplex TaqMan miRNA assay reactions were performed to quantitate miR-21 expression in all 10 tumour samples. For each PCR assay, 2.5 ng of total RNA from LMD samples (0.5 ng/μl) was converted into cDNA using a miRNA-specific reverse transcription step according to the manufacturer’s instructions (Applied Biosystems). PCR reactions were set up in triplicate using miR-21-specific primers and probes and 2 × Universal PCR Master Mix (Applied Biosystems), and performed using the ABI 7500 qPCR instrument and the following cycling parameters: 95 °C for 10 min, 40 cycles of 95 °C for 15 s and 60 oC for 60 s. Expression levels were normalised to U6 snRNA, calculated from the triplicate of CT values using the ΔΔCT method and expressed relative to one of the specimens that was assigned the value 1.
U6B was selected as the endogenous reference gene for the purpose of miRNA validation. Mean triplicate U6B snRNA expression was quantified by the 2−ΔΔCT, allowing expression of miR-21 to be calculated relative to this reference. Mean relative quantities were calculated for each paired tumour and normal tissue sample and a paired Student’s t–test was performed to compare groups.
To quantify expression of epithelial and mesenchymal markers in LMD tissue, 25 ng of total RNA from the stroma or epithelium of a tumour specimen was converted to cDNA.
Subsequently, PCR reactions were set up in triplicate using specific TaqMan primers and probes for CDH1 (HS01023894_ML) VIM (HS00185584_ML), S100A4 (S100A4; HS00243202_ML) and 2 × Universal PCR Master Mix, and performed using the ABI 7500 qPCR instrument and the following cycling parameters: 95 °C for 10 min, 40 cycles of 95 °C for 15 s and 60 °C for 60 s.
In situ hybridisation
ISH was performed as previously described.18 formalin-fixed paraffin-embedded (FFPE) CRC tissue sections (6 μm) were mounted on slides and placed in a Tecan Freedom Evo automated hybridisation instrument (Tecan, Männedorf, Switzerland) in which the following steps were performed: proteinase-K treatment using 15 μg/ml for 8 min at 37 °C, pre-hybridisation for 15 min at 57 °C, hybridisation for 60 min at 57 °C with double DIG-labelled miRCURY LNA probes (Exiqon, Vedbaek, Denmark) for miR-21 and a scramble sequence (both at 40 nM), stringent washes with SSC buffers, DIG blocking reagent (Roche, Mannheim, Germany), alkaline phosphatase-conjugated anti-DIG (Roche), enzymatic development using NBT-BCIP substrate (Roche) for 60 min and finally nuclear fast red counterstain (Vector Laboratories, Burlingame, CA, USA).
Cell culture and transfections
Human CRC cell lines, SW480 and DLD1, and MRC5 lung fibroblast cell were purchased from the European Collection of Cell Culture (Salisbury, UK). Primary colonic fibroblasts were isolated and cultured as described previously.25 Cells were maintained at 37 °C in a humidified atmosphere of 5% CO2 in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% foetal bovine serum (FBS) and 2 mM L-Glutamine.
Stable miR-21 and scrambled control (miR-SCC) miRNA expression in MRC5 fibroblasts (referred to as MRC521 and MRC5SCC cells, respectively) was achieved by transfecting precursor miRNA expression plasmids containing an IRES-driven GFP reporter and selected with puromycin (Genecopoeia, Rockville, MD, USA). PCFs were transiently transfected with miR-21 or miR-SCC plasmid by the same method. All transfections were performed using Xfect transfection reagent (Clontech Laboratories, Mountain View, CA, USA).
Triplicate organotypic models were prepared as previously described.40 Briefly, 5 × 105 MRC521 or MRC5SCC cells were co-cultured with SW480 CRC cells for 14 days before harvest and fixation in formalin. Paraffin-embedded sections were immunostained with anti-cytokeratin antibody to highlight CRC cells or anti-GFP antibody to highlight stably transfected fibroblasts. The middle section of each gel was imaged at × 100 magnification for the purpose of quantitation of invasion. Quantitation was achieved using Image-J image analysis software (NIH), measuring the number and area of invading tumour islands to produce a modified ‘Invasion Index.’41
Cell lysis, SDS-PAGE and western blotting
Cells were lysed in 1 × radioimmunoprecipitation buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris Cl pH 7.5) in the presence of protease inhibitors (Roche). Proteins were separated under reducing conditions in 10% SDS-PAGE gels, transferred onto nitrocellulose membrane, detected with anti-RECK (Abgent, San Diego, CA, USA; AP9259c) or anti-SMA (Sigma; clone 1A4), primary antibodies and horseradish peroxidase-conjugated (Dako, Glostrup, Denmark) secondary antibody. Specific signal was visualised using Supersignal West Pico Chemiluminescent detection kit (Thermo Scientific, Rockford, IL, USA), and band intensity was quantified by densitometry using Image-J. Blots were probed for Hsc-70 or β-actin (Santa Cruz Biotechnology, Dallas, TX, USA) as loading controls.
Cell proliferation and viability assay
CM21/CMSCC were used to treat DLD1 or SW480 CRC cells plated in triplicate at a density of 5000 per well of a 96-well plate. Cell proliferation was measured using the CellTiter 96AQueous One solution Cell Proliferation Assay (Promega, Madison, WI, USA), according to the manufacturer’s instructions. Cell viability was assessed using 5 μl of MTS solution per well, 24 and 48 h after seeding cells. Absorbance readings at 490 nm were taken in triplicate using a spectrophotometric plate reader (Thermo Scientific, Waltham, MA, USA).
Transwell invasion assay
Cell invasion assays were performed over 72 h, as previously described,25 using CM21 and CMSCC supplemented with FBS as chemoattractant. Cells invading the lower chamber were trypsinised and counted using a Casy Cell Counter (Roche Innovatis, Bielefeld, Germany). Specific MMP2 inhibitor I (Merck, Hoddesdon, UK), prepared at a stock concentration of 10 mM in DMSO was also added to the chemoattractant at a final concentration of 25 μM, which achieved maximal inhibition of invasion with no cytotoxic effects (data not shown).
Apoptosis assay
SW480 CRC cells (1 × 105) were plated overnight, in complete DMEM in triplicate wells of a 24-well plate. After 24 h, SW480 cells were washed three times with PBS and treated with 1 ml of CM21 or CMSCC. A further 24 h later, cells were washed and treated either with complete DMEM containing 30 μg/ml Oxaliplatin (Sigma, UK) or unmodified complete DMEM.
Apoptosis was examined using the Annexin V (Ann)/PI double staining method (BD Bioscience, San Jose, CA, USA). Twenty four hours after treatment (oxaliplatin or mock), SW480 cells were trypsinised without washing, resuspended in 300 μl 1 × binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2), pooled and double stained with 2.5 μl Annexin V-FITC (BD Bioscience) and 2.5 μl PI (50 μg/ml). Ten thousand events were acquired per sample using a FACS Canto Flow Cytometer (BD Bioscience). The assay was repeated three times. Results are presented as the percentage of total cells that are viable (Ann−/PI−), early apoptotic (Ann+/PI−) or late apoptotic (Ann+/PI+).
Gelatin zymography
CM21 and CMSCC were prepared in non-reducing 2 × SDS sample buffer and loaded without boiling to a 10% polyacrylamide gel copolymerised with 1 mg/ml of gelatin. Gels were washed twice for 30 min in 2.5% Triton X-100 (Sigma) to remove SDS and incubated in developing buffer (50 mM Tris-HCl, 0.2 M NaCl, 5 mM CaCl2 and 0.02% Triton X-100) at 37 °C overnight. Gels were then stained for 30 min (0.5% Coomassie blue, 30% MeOH, 10% glacial acetic acid) before de-staining (30% MeOH, 10% glacial acetic acid). Gelatin-degrading enzymes were identified as clear bands against the dark background of the gel.
To validate the activity of miR-21 on MMP inhibition, MMP2 inhibitor I (Merck) was either added at a final concentration of 25 μM to CM21/CMSCC for 1 h before fractionation or to developing buffer following fractionation. Images of gels were captured using a UVP Imagestore 5000 (Ultra-Violet Products, Cambridge, UK) and band intensity quantified by Image-J. Results were expressed as relative changes in MMP activity against the scrambled control-transfected cells.
Immunohistochemistry
A monoclonal anti-pan-Cytokeratin antibody (Sigma) and Alexa Fluor 488 conjugate anti-GFP antibody (Invitrogen, Carlsbad, CA, USA) were used for immunohistochemistry on FFPE organotypic sections. Briefly, sections were mounted on APES-coated slides and dried for 24 h at 37 oC, and then dewaxed and rehydrated. Endogenous peroxidase was blocked for 10 min with 0.5% hydrogen peroxidase in methanol. Antigen retrieval was conducted by incubating the sections with protease (Sigma) for 10 min. Anti-pan-Cytokeratin antibody was applied in TBS (pH 7.6) overnight at 4 °C. Swine anti-rabbit IgG-biotinylated secondary antibody (Dako) was applied for 30 min, followed by peroxidase-labelled avidin–biotin complex (Vectastain Elite ABC Reagent, Vector Laboratories) for 30 min. Slides were washed three times with TBS between applications. Positive staining was visualised using DAB+ (Dako) for 5 min counterstained in Mayer’s haematoxylin.
Immunofluorescence
Transiently transfected PCF (PCF21 and PCFSCC) cells (5 × 104) were seeded in 12 wells onto 19 mm circular coverslips sterilised in 100% ethanol. After 12 h, cells were fixed in 4% paraformaldehyde for 15 min, washed three times in PBS-Triton (0.1% Triton X-100) and incubated for 30 min in 3% BSA diluted in PBS-Triton. Primary anti-RECK antibody (1/100 dilution) incubation was performed at 4 °C overnight in a humidified box. The coverslips, then, were washed three times in PBS-Triton and incubated with Alexa Fluor 546-conjugated secondary antibody (1/500) for 1 h at room temperature. Finally, coverslips were mounted onto glass slides using Vectashield Hardset mounting media with DAPI and imaged using an Olympus IX81 fluorescence microscope (Olympus, Southend-on-Sea, UK). Similar methodology was used to assess α-SMA expression in MRC521 and MRC5SCC fibroblasts. Briefly, fibroblasts were treated with complete DMEM or medium extracted from SW480 CRC cells cultured overnight in DMEM (CMSW480), or TGF-β1 (R&D Systems, Minneapolis, MN, USA) at final concentrations of 2 ng/ml or 10 ng/ml. Seventy-two hours later, cells were stained using anti-SMA primary antibody, counterstained and imaged. An Image-J program-based system was used for the identification and quantification of stress fibres. Briefly, the stress fibres were identified by drawing diagonal lines (n=3) along the images and counting sudden and sharp increases in red fluorescence intensity marking individual fibres along the lines.
Statistical analysis
Parametric and non-parametric statistics were expressed as mean±S.E.M. from multiple experiments. Statistical analysis of paired observations was conducted using Student’s t-test or Mann–Whitney U-test. The threshold level of significance was set to 0.05 for all statistical tests.
Change history
01 August 2013
This article has been corrected since Online Publication and a corrigendum has also been published
Abbreviations
- miRNA (miR):
-
microRNA
- CRC:
-
colorectal cancer
- MMP:
-
matrix metalloproteinase
- ECM:
-
extracellular matrix
- PTEN:
-
phosphate and tensin homologue
- PDCD4:
-
programmed cell death 4
- RECK:
-
reversion-inducing cysteine-rich protein with kazal motifs
- TGF-β:
-
transforming growth factor beta
- ISH:
-
in situ hybridisation
- LNA:
-
locked nucleic acid
- LMD:
-
laser microdissection
- qPCR:
-
quantitative PCR
- SMA:
-
smooth muscle actin
- CM:
-
conditioned medium
- GFP:
-
green fluorescent protein
- PCF:
-
primary colon fibroblast
- FFPE:
-
formalin-fixed paraffin-embedded
- DMEM:
-
Dulbecco’s modified Eagle medium
- FBS:
-
foetal bovine serum
- VIM:
-
vimentin
- CDH1:
-
E-Cadherin
- S100A4 (FSP1):
-
S100 calcium-binding protein A4 (fibroblast-specific protein 1)
References
Ferlay J, Parkin DM, Steliarova-Foucher E . Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765–781.
Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V, Faivre J . Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg 2006; 93: 1115–1122.
Coghlin C, Murray GI . Current and emerging concepts in tumour metastasis. J Pathol 2010; 222: 1–15.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342.
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–345.
Casey TM, Eneman J, Crocker A, White J, Tessitore J, Stanley M et al. Cancer associated fibroblasts stimulated by transforming growth factor beta1 (TGF-beta 1) increase invasion rate of tumor cells: a population study. Breast Cancer Res Treat 2008; 110: 39–49.
Guo X, Oshima H, Kitmura T, Taketo MM, Oshima M . Stromal fibroblasts activated by tumor cells promote angiogenesis in mouse gastric cancer. J Biol Chem 2008; 283: 19864–19871.
De Wever O, Demetter P, Mareel M, Bracke M . Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008; 123: 2229–2238.
De Wever O, Nguyen QD, Van Hoorde L, Bracke M, Bruyneel E, Gespach C et al. Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J 2004; 18: 1016–1018.
Blansfield JA, Caragacianu D, Alexander HR 3rd, Tangrea MA, Morita SY, Lorang D et al. Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 2008; 14: 270–280.
Boehm T, Folkman J, Browder T, O’Reilly MS . Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404–407.
Winter J, Jung S, Keller S, Gregory RI, Diederichs S . Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009; 11: 228–234.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834–838.
Slaby O, Svoboda M, Michalek J, Vyzula R . MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer 2009; 8: 102.
Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T . MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133: 647–658.
Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128–2136.
Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 2008; 28: 5369–5380.
Nielsen BS, Jorgensen S, Fog JU, Sokilde R, Christensen IJ, Hansen U et al. High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis 2011; 28: 27–38.
Yao Q, Cao S, Li C, Mengesha A, Kong B, Wei M . Micro-RNA-21 regulates TGF-beta-induced myofibroblast differentiation by targeting PDCD4 in tumor-stroma interaction. Int J Cancer 2011; 128: 1783–1792.
Gaur AB, Holbeck SL, Colburn NH, Israel MA . Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo. Neuro-oncol 2011; 13: 580–590.
Moriyama T, Ohuchida K, Mizumoto K, Yu J, Sato N, Nabae T et al. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 2009; 8: 1067–1074.
Liu M, Tang Q, Qiu M, Lang N, Li M, Zheng Y et al. miR-21 targets the tumor suppressor RhoB and regulates proliferation, invasion and apoptosis in colorectal cancer cells. FEBS Lett 2011; 585: 2998–3005.
Seike M, Goto A, Okano T, Bowman ED, Schetter AJ, Horikawa I et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci USA 2009; 106: 12085–12090.
Mei M, Ren Y, Zhou X, Yuan XB, Han L, Wang GX et al. Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technol Cancer Res Treat 2010; 9: 77–86.
Marsh D, Suchak K, Moutasim KA, Vallath S, Hopper C, Jerjes W et al. Stromal features are predictive of disease mortality in oral cancer patients. J Pathol 2011; 223: 470–481.
Reis ST, Pontes-Junior J, Antunes AA, Dall'Oglio MF, Dip N, Passerotti CC et al. miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer. BMC Urol 2012; 12: 14.
Valeri N, Gasparini P, Fabbri M, Braconi C, Veronese A, Lovat F et al. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci USA 2010; 107: 6982–6987.
Brabletz S, Brabletz T . The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer? EMBO Rep 2010; 11: 670–677.
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704–715.
Ma L, Teruya-Feldstein J, Weinberg RA . Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682–688.
Bullock MD, Sayan AE, Packham GK, Mirnezami AH . MicroRNAs: critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression. Biol Cell 2012; 104: 3–12.
Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, Mathsyaraja H et al. Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol 2012; 14: 159–167.
Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T . Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology 2010; 79: 313–320.
Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425–436.
Takeuchi T, Hisanaga M, Nagao M, Ikeda N, Fujii H, Koyama F et al. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clin Cancer Res 2004; 10: 5572–5579.
Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001; 107: 789–800.
Clark JC, Thomas DM, Choong PF, Dass CR . RECK--a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev 2007; 26: 675–683.
Roy S, Khanna S, Hussain SR, Biswas S, Azad A, Rink C et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 2009; 82: 21–29.
van der Jagt MF, Sweep FC, Waas ET, Hendriks T, Ruers TJ, Merry AH et al. Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer. Cancer Lett 2006; 237: 289–297.
Nystrom ML, Thomas GJ, Stone M, Mackenzie IC, Hart IR, Marshall JF . Development of a quantitative method to analyse tumour cell invasion in organotypic culture. J Pathol 2005; 205: 468–475.
Jenei V, Nystrom ML, Thomas GJ . Measuring invasion in an organotypic model. Methods Mol Biol 2011; 769: 223–232.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Edited by M Agostini
Rights and permissions
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
About this article
Cite this article
Bullock, M., Pickard, K., Nielsen, B. et al. Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression. Cell Death Dis 4, e684 (2013). https://doi.org/10.1038/cddis.2013.213
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cddis.2013.213
Keywords
This article is cited by
-
microRNAs combined to radiomic features as a predictor of complete clinical response after neoadjuvant radio-chemotherapy for locally advanced rectal cancer: a preliminary study
Surgical Endoscopy (2023)
-
MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism
Cancer Chemotherapy and Pharmacology (2021)
-
Exosome-mediated transfer of miR-93-5p from cancer-associated fibroblasts confer radioresistance in colorectal cancer cells by downregulating FOXA1 and upregulating TGFB3
Journal of Experimental & Clinical Cancer Research (2020)
-
An autoregulatory feedback loop of miR-21/VMP1 is responsible for the abnormal expression of miR-21 in colorectal cancer cells
Cell Death & Disease (2020)
-
Altered miR-21, miRNA-148a Expression in Relation to KRAS Mutation Status as Indicator of Adenoma-Carcinoma Transitional Pattern in Colorectal Adenoma and Carcinoma Lesions
Biochemical Genetics (2019)